Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Phase 1positiveNPM-139Positive

AI Analysis

Summary

Vivani Medical announced successful completion of dosing for all participants in the SLIM-1 Phase 1 trial evaluating NPM-139, a miniature ultra long-acting semaglutide implant for chronic weight management.

Clinical Trial Data

Phase

Phase 1

Outcome Details

successful dosing of all participants completed

Importance:5/10

Sentiment:

0.70

weight managementsemaglutideimplantPhase 1clinical trial

Related Companies

$VANI

Read the original article

Published by yahoo_finance on August 6, 2026 12:00 PM

Read Original